Michael Gorin, MD

Michael Gorin, MD discusses the impact of next-day imaging and the potential imaging improvements as physicians await the results of the CLARIFY trial.

Michael Gorin, MD provides the background and results of two key imaging trials that reviewed the efficacy of this new copper-based agent.

A medical expert discusses how emerging copper-based developments in PSMA imaging, particularly the 64Cu-SAR-bisPSMA agent, offer advancements in tumor detection and imaging logistics compared to traditional agents.

A medical expert discusses how advancements in PSMA PET imaging, including the development of agents like 64Cu-SAR-bisPSMA, address current challenges in sensitivity and logistical issues, potentially enhancing tumor detection and patient outcomes.

Prostate cancer experts highlight some closing thoughts and exciting research in progress on prostate cancer imaging.

Neal Shore, MD, FACS, reviews the VISION clinical trial in prostate cancer imaging.

A look at the patient profile of a 62-year-old man presenting with reduced urinary flow and hematuria.

Dr Steven Finkelstein explains a clinical example of a 65-year-old patient with a history of robotic radical prostatectomy for Gleason 9 adenocarcinoma.

Dr Lawrence Saperstein describes the patient profile of a 78-year-old man with a history of intensity-modulated radiation therapy for adenocarcinoma.

Key opinion leaders review the CONDOR clinical trial studying PSMA PET scans for prostate cancer imaging.

Michael Gorin, MD, presents a clinical example of a 60-year-old patient with recurrent prostate cancer.

A panel of experts review whether bone scans still have a place in prostate cancer imaging.

Steven Finkelstein, MD, DABR, FACRO, presents a high-risk prostate cancer patient profile for a 74-year-old man with a history of chronic prostatitis.

Lawrence Saperstein, MD, reviews the patient profile of a 65-year-old man with high-risk prostate cancer.

A look at how PSMA PET imaging fits into the monitoring of a patient with prostate cancer.

A radiation oncologist explains how to discuss the interpretation of prostate cancer imaging with patients in deciding on a treatment plan.

Dr Lawrence Saperstein describes the importance of coronal images and visual analysis in making a thoughtful treatment plan for prostate cancer.

Authors from the OSPREY clinical trial highlight the key take-home messages from the trial outcomes.

Key opinion leaders review the OSPREY clinical trial studying PSMA PET scans for prostate cancer imaging.

Doctors present the patient profile of a 66-year-old man with high-risk localized prostate cancer.

Michael Gorin, MD, describes his experiences with prostate cancer imaging both in academia and community-based practices.

An explanation of the importance of clinical providers following a multidisciplinary approach for prostate cancer management.

Experts review ongoing clinical trials in PSMA PET technology.

The panel explains the science behind PSMA PET scans and reviews the different positron-emitters used in the scans.

A background on the available options and recent advances in prostate cancer imaging.